• Tue news: Regeneron fails to block Eylea biosimilar. Inside the GLP-1 price war. Novartis inks $1B biobucks deal. UCB/Biogen lupus drug. Lilly Alzheimer’s drug approved in Japan. See more on our front page

Biogen's Aduhelm 'likely' linked to Alzheimer's patient's death, RBC analyst says | FiercePharma


<